Is tebentafusp superior to combined immune checkpoint blockade and other systemic treatments in metastatic uveal melanoma? A comparative efficacy analysis with population adjustment
Anne Petzold, Theresa Steeb, Anja Wessely, Elias A. T. Koch, Julio Vera, Carola Berking, Markus V. Heppt
Topics & Concepts
MedicineIpilimumabOncologyInternal medicinePopulationProgression-free survivalConfidence intervalImmune checkpointMelanomaHazard ratioNivolumabSurvival analysisProportional hazards modelImmunotherapyCancerOverall survivalCancer researchEnvironmental healthOcular Oncology and TreatmentsBrain Metastases and TreatmentAutoimmune Neurological Disorders and Treatments